Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease

Neurology. 2001 Oct 23;57(8):1515-7. doi: 10.1212/wnl.57.8.1515.


The antioxidant N-acetylcysteine (NAC) or placebo was administered in a double-blind fashion to patients who met National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria for probable AD. Testing for efficacy occurred after 3 and 6 months of treatment. Comparison of interval change favored NAC treatment on nearly every outcome measure, although significant differences were obtained only for a subset of cognitive tasks.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Acetylcysteine / administration & dosage*
  • Acetylcysteine / adverse effects
  • Alzheimer Disease / drug therapy*
  • Double-Blind Method
  • Female
  • Free Radical Scavengers / administration & dosage*
  • Free Radical Scavengers / adverse effects
  • Humans
  • Male
  • Treatment Outcome


  • Free Radical Scavengers
  • Acetylcysteine